Case Details
- Citation: [2017] SGHC 322
- Case Title: Novartis (Singapore) Pte Ltd v Bristol-Myers Squibb Pharma Co
- Court: High Court of the Republic of Singapore
- Coram: George Wei J
- Date of Decision: 20 December 2017
- Case Number: Originating Summons No 1002 of 2016
- Parties: Novartis (Singapore) Pte Ltd (Applicant) v Bristol-Myers Squibb Pharma Company (Respondent)
- Legal Area: Patents and inventions — Rectification of register
- Procedural Context: Arising in connection with High Court Suit No 1146 of 2015 (Bristol-Myers’ infringement claim relating to acts sought under a product licence)
- Judges: George Wei J
- Counsel for Applicant: Suhaimi bin Lazim, Chow Jian Hong and Yan Chongshuo (Mirandah Law LLP)
- Counsel for Respondent: Alvin Lim Jun Hao and Desmond Chew Tse Sern (Dentons Rodyk & Davidson LLP)
- Patents at Issue: Five Singapore patents under the Patents Act (Cap 221, 2005 Rev Ed): SG 76157, SG 77853, SG 134977, SG 111980, and SG 111981
- Key Substantive Patent Concept: Priority date and entitlement to rely on an earlier application
- Priority Date Claimed by Respondent: 11 June 1988, derived from an earlier US patent application for the same (or similar) invention
- Nature of Error: Wrong earlier US patent application number entered in relevant forms supporting the claimed priority
- Rectification Mechanism Sought: Rectification of the patents register under s 44 of the Patents Act
- Registrar’s Action: Registrar granted requests to correct the register to reflect the correct US patent application number
- Statutes Referenced (as reflected in the judgment extract): Patents Act (Cap 221, 2005 Rev Ed); Medicines Act (Cap 176, 1985 Rev Ed); Patents Rules (Cap 221, R 1, 2007 Rev Ed); Paris Convention; PCT and related instruments (Stockholm Act); TRIPS Agreement; US-Singapore Free Trade Agreement
- International Instruments Referenced: PCT; Paris Convention; EPC (as background to the UK-based structure of Singapore’s Patents Act); Stockholm Act (for PCT priority provisions)
- Judgment Length: 33 pages, 18,897 words
Summary
This High Court decision concerns a dispute over whether the patents register should be rectified after the Registrar corrected an error in the priority information supporting certain Singapore patents. The respondent, Bristol-Myers Squibb Pharma Company (“Bristol-Myers”), was the proprietor of five Singapore patents. After the applicant, Novartis (Singapore) Pte Ltd (“Novartis”), applied for a product licence under the Medicines Act, Bristol-Myers commenced infringement proceedings seeking declarations and injunctive relief. The present originating summons arose because Novartis challenged the validity of Bristol-Myers’ claimed priority date, alleging that the cited earlier US patent application related to a different invention.
The factual turning point was that Bristol-Myers later investigated and discovered that the wrong earlier US patent application number had been entered in the relevant forms during the patent application process. Bristol-Myers then sought corrections from the Registrar, who granted the requests and amended the register to reflect the correct US patent application number. Novartis applied for rectification under s 44 of the Patents Act, arguing that the Registrar should not have allowed the corrections. The High Court (George Wei J) addressed the legal standards governing rectification, the effect of correcting priority information, and the extent to which such corrections could be made where the error was procedural rather than substantive.
What Were the Facts of This Case?
Bristol-Myers owned five Singapore patents under the Patents Act: SG 76157, SG 77853, SG 134977, SG 111980, and SG 111981. The patents concerned pharmaceutical inventions. Novartis, in parallel with the regulatory pathway for generic or follow-on products, applied to the Health Sciences Authority on 30 October 2013 for a product licence for “EFAVIRENZ SANDOZ FILM COATED TABLET 600MG”. On or about 24 September 2015, Novartis served notices of the product licence application on Bristol-Myers pursuant to s 12A(3)(a) of the Medicines Act.
After receiving notice of Novartis’ product licence application, Bristol-Myers commenced High Court Suit No 1146 of 2015 on 9 November 2015. In that suit, Bristol-Myers sought a declaration that the acts for which the product licence was sought would infringe the Singapore patents, and an injunction to prevent those acts. A central contention in the infringement litigation was Bristol-Myers’ entitlement to rely on a priority date of 11 June 1988. That priority date was said to derive from an earlier US patent application relating to the same (or a similar) invention.
Novartis’ defence in the infringement suit challenged the priority claim. Novartis argued that Bristol-Myers was not entitled to rely on the claimed priority date because the document cited in support of that priority related to a completely different invention, with no meaningful connection to the inventions disclosed in the Singapore patents. In other words, Novartis’ position was that the priority information on which Bristol-Myers relied was factually incorrect in a way that could undermine novelty and inventive step assessments at the relevant priority date.
Following the filing of Novartis’ defence, Bristol-Myers investigated the prosecution history and discovered an error: the wrong earlier US patent application number had been entered in the relevant forms during the application process. Bristol-Myers then made requests to the Registrar of Patents (“the Registrar”) to correct the entries in the patents register (“the Register”) so that the correct US patent application number would be reflected in support of the claimed priority date. The Registrar granted the requests and made the corrections. Novartis disagreed and commenced the present originating summons seeking rectification of the Register under s 44 of the Patents Act.
What Were the Key Legal Issues?
The principal legal issue was whether the Registrar’s decision to permit corrections to the register—specifically, corrections to the earlier US patent application number supporting the claimed priority date—should be reversed through rectification proceedings. This required the court to consider the scope and purpose of rectification under s 44, and whether the Registrar’s corrections were legally permissible given the nature of the error.
A related issue concerned the interaction between priority claims and the substantive patentability requirements of novelty, inventive step, and industrial applicability. The court needed to understand how priority dates are determined under the Patents Act, including the statutory framework for claiming priority from earlier applications (including convention and PCT-based systems). The legal question was not merely whether an error occurred, but whether correcting the register could restore the correct priority basis for the patents without improperly altering the substantive rights in a way that would prejudice third parties.
Finally, the case raised a procedural fairness dimension. Novartis effectively argued that it should be able to rely on the incorrect priority information as it appeared on the register, and that the Registrar’s correction should not be allowed after the fact, particularly where the correction could affect the outcome of infringement proceedings. The court therefore had to balance the correction of genuine clerical or administrative mistakes against the need for certainty and reliance interests in the patent register.
How Did the Court Analyse the Issues?
Before turning to the rectification dispute, the court provided a detailed overview of Singapore’s patent system and the legal architecture for priority. George Wei J emphasised that Singapore’s Patents Act is based on the UK Patents Act 1977, which itself is based on the European Patent Convention 1973. This background matters because it informs how concepts such as priority, convention claims, and procedural mechanisms are understood within Singapore’s statutory scheme.
The court then explained the substantive requirements for patentability—novelty, inventive step, and capability of industrial application—and noted that these are assessed by reference to the state of the art at the priority date of the claimed invention. The priority date is generally the filing date under s 17(1), but an earlier date may be claimed under s 17(2) where there is an earlier application within the preceding 12 months. The court also described how earlier applications may be from “convention countries” and the requirement for declarations within prescribed periods.
Importantly, the court addressed the PCT framework. Singapore is a contracting state to the PCT, and the PCT provides an international system for filing patent applications. Under the PCT and related instruments, an international application can claim priority based on an earlier application, and the priority claim must indicate the date and number of the earlier application. The court linked this to Singapore’s Patents Act provisions on international applications, including that an international application designating Singapore is treated as if it were an application under the Patents Act, and that declarations of priority made under the PCT are treated as declarations under s 17(2). This analysis supported the court’s understanding that priority information is not merely a formal detail; it is a statutory gateway to the relevant priority date for assessing patentability.
With this framework in place, the court turned to the specific dispute: whether the Registrar could correct the register to reflect the correct earlier US patent application number. The court recognised that Singapore does not have pre-grant opposition by third parties, unlike some jurisdictions. That point was relevant because it underscores that the patent register and the information it contains may be relied upon by later parties, including those who must decide how to respond to patent rights in the context of regulatory licensing and infringement risk. However, the absence of pre-grant opposition does not mean that errors cannot be corrected; rather, it heightens the importance of ensuring that corrections are made within the legal boundaries of the Patents Act and are consistent with the purpose of rectification.
Although the extract provided is truncated, the court’s approach can be understood from the structure of the judgment: it first set out the statutory and international context for priority claims, then described the factual genesis of the error and correction, and finally addressed the rectification standard under s 44. The core reasoning would necessarily involve determining whether the error was the kind of mistake that rectification is designed to address (for example, a clerical or administrative error in the identification of an earlier application) and whether the correction would align the register with what was actually intended and supported by the underlying priority claim.
In assessing Novartis’ challenge, the court also had to consider the practical consequences for the infringement suit. If the priority date were invalid because the cited earlier application was unrelated, Bristol-Myers’ patents could be exposed to novelty or inventive step attacks at a later effective date. Conversely, if the register could be corrected to reflect the correct earlier application number, Bristol-Myers would be able to rely on the intended priority basis. The court therefore had to ensure that rectification did not amount to a substantive alteration of the invention or a retroactive expansion of rights, but instead corrected the record to reflect the true priority information.
What Was the Outcome?
The High Court dismissed Novartis’ application for rectification of the patents register. As a result, the corrections made by the Registrar remained in place, and the register continued to reflect the correct earlier US patent application number supporting the claimed priority date of 11 June 1988.
Practically, this meant that Novartis could not rely on the incorrect priority information as it originally appeared to undermine Bristol-Myers’ priority claim. The corrected register would therefore be the operative record for the priority analysis in the related infringement proceedings.
Why Does This Case Matter?
This case is significant for patent practitioners because it addresses the limits and proper use of rectification proceedings in Singapore, particularly where the dispute concerns priority information rather than the technical content of the invention. Priority claims are central to patent validity and infringement analysis because they determine the relevant state of the art for novelty and inventive step. Where an error occurs in identifying an earlier application, the question becomes whether the patent system can correct the record without undermining certainty and reliance.
The decision also has practical implications for parties engaged in the Medicines Act product licence ecosystem. When a generic or follow-on applicant gives notice of a product licence application, the patentee’s ability to rely on its patents—including priority—can determine litigation strategy and risk assessment. This case illustrates that even if a priority-related error is initially exploited in defence, the patentee may be able to cure the record through Registrar corrections that survive subsequent rectification challenges, provided the legal requirements are met.
From a doctrinal perspective, the judgment reinforces that Singapore’s patent framework—shaped by UK and European influences and integrated with PCT priority mechanisms—treats priority information as a structured legal concept. Rectification is therefore not merely a housekeeping exercise; it is a mechanism that can affect substantive rights. Practitioners should therefore ensure that priority data submitted in forms and declarations is accurate, and where errors are discovered, that correction requests are pursued promptly and with evidential support.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed), including s 17 (priority), s 44 (rectification of register)
- Medicines Act (Cap 176, 1985 Rev Ed), including s 12A(3)(a) (notice in connection with product licence applications)
- Patents Rules (Cap 221, R 1, 2007 Rev Ed), including provisions relating to forms and procedures for patent applications
- Patent Cooperation Treaty (PCT)
- Paris Convention for the Protection of Industrial Property
- Stockholm Act (as referenced in the PCT priority provisions)
- TRIPS Agreement
- US-Singapore Free Trade Agreement
Cases Cited
- [2017] SGHC 322 (the present case)
Source Documents
This article analyses [2017] SGHC 322 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.